Ambry Genetics Launches Whole Genome Sequencing Tests to Improve Rare Disease Diagnosis
Ambry Genetics, a wholly owned subsidiary of Tempus AI (NASDAQ:TEM), has introduced GenomeNext and GenomeReveal, a new whole…
Browsing Category